Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
How are you using circulating tumor DNA in your clinical decisions for HPV-associated OPSCC?
Answer from: Radiation Oncologist at Academic Institution
We have a post-operative trial where we are using cfDNA as an integral marker to decide on adjuvant therapy for HPV+ OPC.
Sign in or Register to read more
12429
Related Questions
Is there a role for bromhexine for thick secretions during/after head and neck RT?
Would you modify your treatment approach for treating an HPV-positive head and neck cancer in a patient with symptomatic Sjogren's?
What dose and regimen would you treat a stage I laryngeal cancer s/p R1 resection?
Are there any special treatment considerations when treating a patient with laryngeal cancer with significant Reinke's edema of the vocal folds?
What is the recommended treatment approach for stage III/IVA nasopharyngeal cancer that is p16 negative and EBV positive?
What dose would you use for a plaque brachytherapy for a melanoma involving the iris?
Would you consider palliative RT in the setting of tumor causing osteonecrosis in an elderly patient?
Would you consider 50 Gy in 20 fractions for a primary head and neck malignancy in an elderly patient with poor KPS?
What is the recommended adjuvant dose for neuroendocrine cancer in the head and neck?
How would you approach SCC of unknown primary, p16-, EBV-, metastatic to a large 5.5 cm level 2 neck node, if you suspect a cutaneous origin after clinical workup?